Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243352 | 0.91 | TP53 (0.49) | TP53CYP3A4LMNAHCRTR2 | |
| SCHEMBL21243380 | 0.79 | TP53 (0.35) | TP53CYP3A4LMNA | |
| SCHEMBL21243375 | 0.78 | TRPM8 (0.41) | TP53CYP3A4LMNAHCRTR2 | |
| SCHEMBL17124766 | 0.77 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL15071084 | 0.76 | SHBG (0.34) | LMNAHCRTR2 | |
| SCHEMBL11882934 | 0.74 | HCRTR2 (0.38) | LMNAHCRTR2 | |
| SCHEMBL11880271 | 0.74 | HCRTR2 (0.38) | LMNAHCRTR2 | |
| SCHEMBL6559290 | 0.74 | HCRTR2 (0.38) | LMNAHCRTR2 | |
| SCHEMBL21243383 | 0.74 | ALDH1A1 (0.38) | LMNAHCRTR2 | |
| SCHEMBL14980686 | 0.73 | TP53 (0.49) | TP53CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46698-E1 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-RE46698-E1 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| US-9492364-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-9492364-B2 | Use of cyclohexanol derivatives as antimicrobial active compounds | MERCK PATENT GMBH (DE) | 2016-11-15 | — | — | US | disclosed |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| WO-2015082034-A1 | USE OF CYCLOHEXANOIC ACID DERIVATIVES AS PLASTICIZERS | MERCK PATENT GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| WO-2013091775-A2 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE INGREDIENTS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335029-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | CYP51A1, DDT, EBP | TP53 4589/4885CYP3A4 115/4885LMNA 4136/4885 |
| US-20160326091-A1 | USE OF CYCLOHEXANOL DERIVATIVES AS ANTIMICROBIAL ACTIVE COMPOUNDS | CYP51A1, DDT, EBP | TP53 4589/4885CYP3A4 115/4885LMNA 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.